Oppenheimer upgraded Nektar (NKTR) to Outperform from Perform with a $6 price target The firm is refreshing its model ahead of the company’s rezpegaldesleukin in atopic dermatitis – AD ...
Cash Runway: Expected to extend into Q4 2026. Nektar Therapeutics (NASDAQ:NKTR) completed enrollment for its Phase IIB studies in atopic dermatitis and alopecia areata on schedule, demonstrating ...
Nektar Therapeutics NKTR incurred an adjusted loss per share of 15 cents in the fourth quarter of 2024, wider than the Zacks Consensus Estimate of a loss of 13 cents. In the year-ago quarter, the ...
William Blair analyst Andy Hsieh reiterated a Hold rating on Nektar Therapeutics (NKTR – Research Report) today. The company’s shares closed yesterday at $0.82. Easily identify stocks' risks ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback